For example, it has been demonstrated that increased TAM infiltration is associated with a poorer CD19-CAR-T cell therapy outcome against B-cell non-Hodgkin’s lymphoma (65). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.